Products

ComforJet^® is an automated injection device ​compatible with 1.0 –2.25 mL pre-filled syringes, featuring ​two-step operation for intuitive administration and ​broad patient applicability.

The Reconeer® Transjugular Intrahepatic Puncture Biopsy Kit involves insertion of a catheter through the jugular vein, creation of a venous channel through a guide, and delivery of a biopsy needle into the liver, ultimately obtaining liver histopathology.

Launched in 2021, EqualSpheres^® Narrow-size Embolic Microspheres incorporates patented technology and has obtained approvals from both the China NMPA and the USA FDA (510k). It is intended to be used for the embolization of arteriovenous malformations (AVMs) and hyper vascular tumors, including uterine fibroids. So far, it’s successfully deployed in thousands of hospitals and primarily employed for the embolization treatment of various solid malignant tumors, including primary liver cancer, metastatic liver cancer, lung cancer, kidney cancer, cervical cancer, prostate cancer, and soft tissue sarcoma.

Launched in 2021, EvenSpheres^® Narrow-size Embolic Microspheres incorporates patented technology and has obtained approvals from both the China NMPA and the USA FDA (510k). It is intended to be used for the embolization of arteriovenous malformations (AVMs) and hyper vascular tumors, including uterine fibroids. So far, it’s successfully deployed in thousands of hospitals and primarily employed for the embolization treatment of various solid malignant tumors, including primary liver cancer, metastatic liver cancer, lung cancer, kidney cancer, cervical cancer, prostate cancer, and soft tissue sarcoma.

Launched in 2015, CalliSpheres^® Embolic Microspheres incorporates patented technology and has obtained approvals from both the China NMPA and the USA FDA (510k). It is intended to be used for the embolization of arteriovenous malformations (AVMs) and hyper vascular tumors, including uterine fibroids. So far, it’s successfully deployed in thousands of hospitals and primarily employed for the embolization treatment of various solid malignant tumors, including primary liver cancer, metastatic liver cancer, lung cancer, kidney cancer, cervical cancer, prostate cancer, and soft tissue sarcoma.

Launched in 2015, 8Spheres^® Embolic Microspheres incorporates patented technology and has obtained approvals from both the China NMPA and the USA FDA (510k). It is intended to be used for the embolization of arteriovenous malformations (AVMs) and hyper vascular tumors, including uterine fibroids. So far, it’s successfully deployed in thousands of hospitals and primarily employed for the embolization treatment in benign conditions such as hemoptysis, splenomegaly, uterine fibroids, adenomyosis, and benign prostatic hyperplasia.